{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:07:00Z","timestamp":1790712420669,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3DA047003"],"award-info":[{"award-number":["UH3DA047003"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-026-10838-0","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:19:01Z","timestamp":1790709541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations"],"prefix":"10.1007","author":[{"given":"Hazar","family":"Khidir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Nedelec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie S.","family":"Sebok-Syer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber K.","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikgyu","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Melnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6045-7342","authenticated-orcid":false,"given":"Michelle P.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"10838_CR1","unstructured":"Products - Vital Statistics Rapid Release - Provisional Drug Overdose Data. June 27, 2025. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed 11 Aug 2025."},{"issue":"16","key":"10838_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","volume":"313","author":"G D\u2019Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, O\u2019Connor PG, Pantalon MV, et al. Emergency Department\u2013Initiated Buprenorphine\/Naloxone Treatment for Opioid Dependence. JAMA. 2015;313(16):1636-1644. https:\/\/doi.org\/10.1001\/jama.2015.3474.","journal-title":"JAMA."},{"key":"10838_CR3","doi-asserted-by":"publisher","unstructured":"Weiner SG, Little K, Yoo J, et al. Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit. JAMA Netw Open. 2024;7(7):e2423954. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.23954.","DOI":"10.1001\/jamanetworkopen.2024.23954"},{"key":"10838_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ajem.2022.02.041","volume":"55","author":"QR Reuter","year":"2022","unstructured":"Reuter QR, Santos AD, McKinnon J, Gothard D, Jouriles N, Seaberg D. Long-term treatment retention of an emergency department initiated medication for opioid use disorder program. Am J Emerg Med. 2022;55:98-102. https:\/\/doi.org\/10.1016\/j.ajem.2022.02.041.","journal-title":"Am J Emerg Med."},{"issue":"9","key":"10838_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine Treatment Divide by Race\/Ethnicity and Payment. JAMA Psychiatry. 2019;76(9):979-981. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0876.","journal-title":"JAMA Psychiatry."},{"issue":"2","key":"10838_CR6","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open."},{"issue":"4","key":"10838_CR7","doi-asserted-by":"publisher","first-page":"e203711","DOI":"10.1001\/jamanetworkopen.2020.3711","volume":"3","author":"WC Goedel","year":"2020","unstructured":"Goedel WC, Shapiro A, Cerd\u00e1 M, Tsai JW, Hadland SE, Marshall BDL. Association of Racial\/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States. JAMA Netw Open. 2020;3(4):e203711. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.3711.","journal-title":"JAMA Netw Open."},{"key":"10838_CR8","doi-asserted-by":"publisher","first-page":"112636","DOI":"10.1016\/j.drugalcdep.2025.112636","volume":"270","author":"AS Tilhou","year":"2025","unstructured":"Tilhou AS, Gasman S, Wang J, et al. Assessing inequities in buprenorphine treatment across the care cascade. Drug Alcohol Depend. 2025;270:112636. https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112636.","journal-title":"Drug Alcohol Depend."},{"key":"10838_CR9","doi-asserted-by":"publisher","first-page":"107296","DOI":"10.1016\/j.addbeh.2022.107296","volume":"130","author":"EG Guerrero","year":"2022","unstructured":"Guerrero EG, Amaro H, Khachikian T, Zahir M, Marsh JC. A bifurcated opioid treatment system and widening insidious disparities. Addict Behav. 2022;130:107296. https:\/\/doi.org\/10.1016\/j.addbeh.2022.107296.","journal-title":"Addict Behav."},{"issue":"19","key":"10838_CR10","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","volume":"388","author":"ML Barnett","year":"2023","unstructured":"Barnett ML, Meara E, Lewinson T, et al. Racial Inequality in Receipt of Medications for Opioid Use Disorder. N Engl J Med. 2023;388(19):1779-1789. https:\/\/doi.org\/10.1056\/NEJMsa2212412.","journal-title":"N Engl J Med."},{"issue":"5","key":"10838_CR11","doi-asserted-by":"publisher","first-page":"e205852","DOI":"10.1001\/jamanetworkopen.2020.5852","volume":"3","author":"AS Kilaru","year":"2020","unstructured":"Kilaru AS, Xiong A, Lowenstein M, et al. Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients. JAMA Netw Open. 2020;3(5):e205852. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.5852.","journal-title":"JAMA Netw Open."},{"issue":"5","key":"10838_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.amepre.2022.05.006","volume":"63","author":"CC Dunphy","year":"2022","unstructured":"Dunphy CC, Zhang K, Xu L, Guy GP. Racial\u2012Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid. Am J Prev Med. 2022;63(5):717-725. https:\/\/doi.org\/10.1016\/j.amepre.2022.05.006.","journal-title":"Am J Prev Med."},{"issue":"16","key":"10838_CR13","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1007\/s11606-023-08306-0","volume":"38","author":"KY Xu","year":"2023","unstructured":"Xu KY, Schiff DM, Jones HE, et al. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA. J Gen Intern Med. 2023;38(16):3499-3508. https:\/\/doi.org\/10.1007\/s11606-023-08306-0.","journal-title":"J Gen Intern Med."},{"key":"10838_CR14","unstructured":"DQ Atlas Race & Ethnicity Beneficiary Information. Medicaid. https:\/\/www.medicaid.gov\/dq-atlas\/downloads\/background-and-methods\/TAF-DQ-Race-Ethnicity.pdf."},{"issue":"6","key":"10838_CR15","doi-asserted-by":"publisher","first-page":"e231574","DOI":"10.1001\/jamahealthforum.2023.1574","volume":"4","author":"SR Lindner","year":"2023","unstructured":"Lindner SR, Hart K, Manibusan B, McCarty D, McConnell KJ. State- and County-Level Geographic Variation in Opioid Use Disorder, Medication Treatment, and Opioid-Related Overdose Among Medicaid Enrollees. JAMA Health Forum. 2023;4(6):e231574. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.1574.","journal-title":"JAMA Health Forum."},{"key":"10838_CR16","unstructured":"Welcome - DQ Atlas. https:\/\/www.medicaid.gov\/dq-atlas\/welcome. Accessed 6 Aug 2025."},{"key":"10838_CR17","unstructured":"Gordon S, Johnson A, Kennedy S, McConnell J, Schpero W. Catalyzing Medicaid Policy Research with T-MSIS Analytic Files (TAF): Learnings from Year 1 of the Medicaid Data Learning Network (MDLN). Academy Health; 2023. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/academyhealth.org\/sites\/default\/files\/publication\/%5Bfield_date%3Acustom%3AY%5D-%5Bfield_date%3Acustom%3Am%5D\/ah_mdln_summary_report_2023_final.pdf."},{"key":"10838_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12875-024-02609-9","volume":"25","author":"SA Hooker","year":"2024","unstructured":"Hooker SA, Starkey C, Bart G, Rossom RC, Kane S, Olson AW. Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings. BMC Prim Care. 2024;25:361. https:\/\/doi.org\/10.1186\/s12875-024-02609-9.","journal-title":"BMC Prim Care."},{"issue":"3","key":"10838_CR19","first-page":"29","volume":"21","author":"R Kronick","year":"2000","unstructured":"Kronick R, Gilmer T, Dreyfus T, Lee L. Improving Health-Based Payment for Medicaid Beneficiaries: CDPS. Health Care Financ Rev. 2000;21(3):29-64.","journal-title":"Health Care Financ Rev."},{"key":"10838_CR20","unstructured":"National Academies of Sciences E, Division H and M, Policy B on HS, et al. Pain Management and the Intersection of Pain and Opioid Use Disorder. In: Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. National Academies Press (US); 2017. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK458655\/. Accessed 6 Aug 2025."},{"key":"10838_CR21","doi-asserted-by":"publisher","first-page":"100292","DOI":"10.1016\/j.dadr.2024.100292","volume":"13","author":"A Burke","year":"2024","unstructured":"Burke A, Vadiei N, Mollon L. Prevalence, patterns, and predictors of prescribing medications for opioid use disorder (MOUD) in the Inpatient setting. Drug Alcohol Depend Rep. 2024;13:100292. https:\/\/doi.org\/10.1016\/j.dadr.2024.100292.","journal-title":"Drug Alcohol Depend Rep."},{"issue":"6","key":"10838_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1377\/hlthaff.2020.02261","volume":"40","author":"B Andraka-Christou","year":"2021","unstructured":"Andraka-Christou B. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder. Health Aff (Millwood). 2021;40(6):920-927. https:\/\/doi.org\/10.1377\/hlthaff.2020.02261.","journal-title":"Health Aff (Millwood)."},{"key":"10838_CR23","doi-asserted-by":"publisher","unstructured":"The Medicaid Outcomes Distributed Research Network (MODRN). Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014\u20132018. JAMA. 2021;326(2):154\u2013164. https:\/\/doi.org\/10.1001\/jama.2021.7374.","DOI":"10.1001\/jama.2021.7374"},{"key":"10838_CR24","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ."},{"key":"10838_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jsat.2016.12.001","volume":"74","author":"JI Manuel","year":"2017","unstructured":"Manuel JI, Yuan Y, Herman D, et al. Barriers and Facilitators to Successful Transition from Long-Term Residential Substance Abuse Treatment. J Subst Abuse Treat. 2017;74:16-22. https:\/\/doi.org\/10.1016\/j.jsat.2016.12.001.","journal-title":"J Subst Abuse Treat."},{"key":"10838_CR26","doi-asserted-by":"publisher","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1\u201391. https:\/\/doi.org\/10.1097\/ADM.0000000000000633.","DOI":"10.1097\/ADM.0000000000000633"},{"issue":"7","key":"10838_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/acem.14668","volume":"30","author":"WC Holland","year":"2023","unstructured":"Holland WC, Li F, Nath B, et al. Racial and ethnic disparities in emergency department\u2013initiated buprenorphine across five health care systems. Acad Emerg Med. 2023;30(7):709-720. https:\/\/doi.org\/10.1111\/acem.14668.","journal-title":"Acad Emerg Med."},{"issue":"5","key":"10838_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.amepre.2022.05.006","volume":"63","author":"CC Dunphy","year":"2022","unstructured":"Dunphy CC, Zhang K, Xu L, Guy GP. Racial\u2012Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid. Am J Prev Med. 2022;63(5):717-725. https:\/\/doi.org\/10.1016\/j.amepre.2022.05.006.","journal-title":"Am J Prev Med."},{"issue":"4","key":"10838_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1370\/afm.2099","volume":"15","author":"CHA Andrilla","year":"2017","unstructured":"Andrilla CHA, Coulthard C, Larson EH. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder. Ann Fam Med. 2017;15(4):359-362. https:\/\/doi.org\/10.1370\/afm.2099.","journal-title":"Ann Fam Med."},{"key":"10838_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ajem.2021.03.056","volume":"47","author":"AS Kilaru","year":"2021","unstructured":"Kilaru AS, Liu M, Gupta R, et al. Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal. Am J Emerg Med. 2021;47:154-157. https:\/\/doi.org\/10.1016\/j.ajem.2021.03.056.","journal-title":"Am J Emerg Med."},{"issue":"6","key":"10838_CR31","doi-asserted-by":"publisher","first-page":"e2215287","DOI":"10.1001\/jamanetworkopen.2022.15287","volume":"5","author":"MA Stevens","year":"2022","unstructured":"Stevens MA, Tsai J, Savitz ST, et al. Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020. JAMA Netw Open. 2022;5(6):e2215287. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.15287.","journal-title":"JAMA Netw Open."},{"issue":"1","key":"10838_CR32","doi-asserted-by":"publisher","first-page":"e2353771","DOI":"10.1001\/jamanetworkopen.2023.53771","volume":"7","author":"AA Herring","year":"2024","unstructured":"Herring AA, Rosen AD, Samuels EA, et al. Emergency Department Access to Buprenorphine for Opioid Use Disorder. JAMA Netw Open. 2024;7(1):e2353771. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.53771.","journal-title":"JAMA Netw Open."},{"key":"10838_CR33","unstructured":"Waiver Elimination (MAT Act). November 6, 2024. https:\/\/www.samhsa.gov\/substance-use\/treatment\/statutes-regulations-guidelines\/mat-act. Accessed 6 Aug 2025."},{"issue":"1","key":"10838_CR34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","volume":"26","author":"ND Volkow","year":"2021","unstructured":"Volkow ND, Blanco C. The Changing Opioid Crisis: development, challenges and opportunities. Mol Psychiatry. 2021;26(1):218-233. https:\/\/doi.org\/10.1038\/s41380-020-0661-4.","journal-title":"Mol Psychiatry."},{"issue":"6","key":"10838_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1176\/appi.ps.201500228","volume":"67","author":"B Saloner","year":"2016","unstructured":"Saloner B, Stoller KB, Barry CL. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. Psychiatr Serv. 2016;67(6):676-679. https:\/\/doi.org\/10.1176\/appi.ps.201500228.","journal-title":"Psychiatr Serv."},{"issue":"11","key":"10838_CR36","doi-asserted-by":"publisher","first-page":"e224001","DOI":"10.1001\/jamahealthforum.2022.4001","volume":"3","author":"AJ Abraham","year":"2022","unstructured":"Abraham AJ, Andrews CM, Harris SJ, Westlake MM, Grogan CM. Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care. JAMA Health Forum. 2022;3(11):e224001. https:\/\/doi.org\/10.1001\/jamahealthforum.2022.4001.","journal-title":"JAMA Health Forum."},{"issue":"9","key":"10838_CR37","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/add.14634","volume":"114","author":"RG Frank","year":"2019","unstructured":"Frank RG, Fry CE. The impact of expanded Medicaid eligibility on access to naloxone. Addict Abingdon Engl. 2019;114(9):1567-1574. https:\/\/doi.org\/10.1111\/add.14634.","journal-title":"Addict Abingdon Engl."},{"key":"10838_CR38","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.dadr.2022.100126","volume":"6","author":"RM Bohler","year":"2022","unstructured":"Bohler RM, Freeman PR, Villani J, et al. The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses. Drug Alcohol Depend Rep. 2022;6:100126. https:\/\/doi.org\/10.1016\/j.dadr.2022.100126.","journal-title":"Drug Alcohol Depend Rep."},{"issue":"4","key":"10838_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/ADM.0000000000000757","volume":"15","author":"KM Lillie","year":"2021","unstructured":"Lillie KM, Shaw J, Jansen KJ, Garrison MM. Buprenorphine\/Naloxone for Opioid Use Disorder Among Alaska Native and American Indian People. J Addict Med. 2021;15(4):297-302. https:\/\/doi.org\/10.1097\/ADM.0000000000000757.","journal-title":"J Addict Med."},{"key":"10838_CR40","doi-asserted-by":"publisher","unstructured":"Polsky DE, Sen AP, Arsenault S. Innovative Payment to Scale up Access to Medications for Opioid Use Disorder. Am J Manag Care. 2020;26(7):286\u2013287. https:\/\/doi.org\/10.37765\/ajmc.2020.43757.","DOI":"10.37765\/ajmc.2020.43757"},{"key":"10838_CR41","unstructured":"Medicaid Managed Care Tracker. KFF. https:\/\/www.kff.org\/statedata\/collection\/medicaid-managed-care-tracker\/. Accessed 11 Aug 2025."},{"issue":"4","key":"10838_CR42","doi-asserted-by":"publisher","first-page":"e181588","DOI":"10.1001\/jamanetworkopen.2018.1588","volume":"1","author":"B Saloner","year":"2018","unstructured":"Saloner B, Levin J, Chang HY, Jones C, Alexander GC. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion. JAMA Netw Open. 2018;1(4):e181588. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.1588.","journal-title":"JAMA Netw Open."},{"key":"10838_CR43","unstructured":"Greene K, Repka S, Thieme M, Stewart L, Saunders R. Challenges and Opportunities for Integrating Substance Use Disorder Treatment into Community Health Centers. Duke University; 2022."},{"issue":"1","key":"10838_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12954-024-01070-2","volume":"21","author":"G Luna","year":"2024","unstructured":"Luna G, Dermid G, Unger JB. Fentanyl harm reduction strategies among Latinx communities in the United States: a scoping review. Harm Reduct J. 2024;21(1):150. https:\/\/doi.org\/10.1186\/s12954-024-01070-2.","journal-title":"Harm Reduct J."},{"issue":"2","key":"10838_CR45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/add.16691","volume":"120","author":"X Zang","year":"2025","unstructured":"Zang X, Skinner A, Li Z, et al. Improving racial\/ethnic health equity and naloxone access among people at risk for opioid overdose: A simulation modeling analysis of community-based naloxone distribution strategies in Massachusetts, United States. Addict Abingdon Engl. 2025;120(2):316-326. https:\/\/doi.org\/10.1111\/add.16691.","journal-title":"Addict Abingdon Engl."},{"key":"10838_CR46","unstructured":"Petit-Homme B. Strengthening Behavioral Health Systems Through Medicaid: Three Strategies for State Action - CHCS Blog. Center for Health Care Strategies. July 8, 2025. https:\/\/www.chcs.org\/strengthening-behavioral-health-systems-through-medicaid-three-strategies-for-state-action\/. Accessed 11 Aug 2025."},{"key":"10838_CR47","unstructured":"Reducing Substance Use Disorders | Medicaid. https:\/\/www.medicaid.gov\/resources-for-states\/innovation-accelerator-program\/program-areas\/reducing-substance-use-disorders. Accessed 11 Aug 2025."},{"issue":"8","key":"10838_CR48","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s11606-017-4077-z","volume":"32","author":"SE Wakeman","year":"2017","unstructured":"Wakeman SE, Metlay JP, Chang Y, Herman GE, Rigotti NA. Inpatient Addiction Consultation for Hospitalized Patients Increases Post-Discharge Abstinence and Reduces Addiction Severity. J Gen Intern Med. 2017;32(8):909-916. https:\/\/doi.org\/10.1007\/s11606-017-4077-z.","journal-title":"J Gen Intern Med."},{"key":"10838_CR49","unstructured":"Bureau UC. New Research Links Medicaid and Census Bureau Data to Improve Study of Racial\/Ethnic Health Disparities. Census.gov. https:\/\/www.census.gov\/library\/stories\/2023\/04\/missing-medicaid-data-on-race-ethnicity-may-bias-health-research.html. Accessed 11 Aug 2025."},{"issue":"16","key":"10838_CR50","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","volume":"313","author":"G D\u2019Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, O\u2019Connor PG, Pantalon MV, et al. Emergency Department\u2013Initiated Buprenorphine\/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial. JAMA. 2015;313(16):1636-1644. https:\/\/doi.org\/10.1001\/jama.2015.3474.","journal-title":"JAMA."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10838-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10838-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10838-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:19:04Z","timestamp":1790709544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10838-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":50,"alternative-id":["10838"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10838-0","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MPL received funding from the National Heart, Lung, and Blood Institute, National Institute on Aging, Agency for Healthcare Research and Quality, and Emergency Medicine Foundation for unrelated work.ERM received funding from the National Institute On Drug Abuse, Agency for Healthcare Research and Quality, and the American Medical Association unrelated to this work.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors reports no conflicts of interest.","order":4,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}